AMWL vs AZN

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low Price/Book and Price/Sales ratio suggesting potential value, persistent unprofitability, negative earnings momentum, and deteriorating revenue growth paint a bleak picture. Insider selling activity and a lack of analyst consensus further undermine confidence, while the company's long-term price performance has been catastrophic, down 99.3% over five years. Although the balance sheet shows low leverage and strong liquidity, these are overshadowed by systemic profitability and growth failures.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.